Zhongmin Alex Ma, Ph. D.
- Founder/Chief Executive Officer, Revivallon Biopharmaceutical Co. Ltd.
- Adjunct Investigator, Zhuhai Fudan Innovation Institute, Fudan University
Dr. Zhongmin Ma is the founder and Chief Executive Officer of Revivallon Biopharmaceutical Co. Ltd, a company dedicated to the development of innovative drugs with potential to cure diabetes. He is also an Adjunct Investigator of Zhuhai Fudan Innovation Institute, Fudan University. Dr. Ma has more than 30 years’ experience in diabetes research and drug development. Prior to founding Revivallon, he served as the Chief Scientific Officer of Diapin Therapeutics, USA, a company to develop innovative drugs to treat metabolic diseases. Before that, Dr. Ma was a professor at Mount Sinai School of Medicine (MSSM) in New York, where his laboratory made breakthrough discoveries in β-cell regeneration in vivo. This groundbreaking work paved the way for developing novel drugs with potential to cure diabetes. Dr. Ma was one of the founders of Chinese American Diabetes Association (CADA) and served as the President for one term. He got his Ph. D. degree in Biochemistry from St. Louis University School of Medicine and his B.S. degree in Biology from Fudan University, Shanghai, China.